Repeat renal allografts treated with sirolimus, cyclosporine, anti-thymocyte globulin induction and continuous steroids achieve similar immunosuppressive efficacy as primary transplants

Clinical Transplantation

Volumn 24, Issue 2, 2010, Pages 243-251

  Petero, Virgilio G ^a   Kaposztas, Zsolt ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Kidney transplantation; Retransplant; Sirolimus

Indexed keywords

CYCLOSPORIN A; RAPAMYCIN; STEROID; THYMOCYTE ANTIBODY;

ADULT; AGE; ARTICLE; COLD ISCHEMIA; CONTROLLED STUDY; DEMOGRAPHY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HLA MATCHING; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETRANSPLANTATION; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; REOPERATION; SIROLIMUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 77952949708     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2009.01055.x     Document Type: Article

References (30)

1. Rao PS, Schaubel DE, Guanghui W, Fenton SA. Evaluating the survival benefit of kidney retransplantation. Transplantation 2006, 82:669.
2. Eggers PN. Effect of transplantation on the Medicare end-stage renal disease program. N Engl J Med 1988, 318:223.
3. Almond PS, Matas AJ, Gillingham K. Risk factors for second renal allografts immunosuppressed with cyclosporine. Transplantation 1991, 52:253.
4. Evans RW, Manninen DL, Dong FB, McLynne DA. Is retransplantation cost effective? Transplant Proc 1993, 25(1 Pt 2).
5. Howard RJ, Reed AI, Van Der Werf WJ, Hemming AW, Patton PR, Scornik JC. What happens to renal transplant recipients who lose their grafts? Am J Kidney Dis 2001, 38:31.
6. Magee JC, Barr ML, Basadonna GP. Repeat organ transplant in the United States 1996-2005. Am J Transplant 2007, 7:1424.
7. Flechner SM, Lorber MI, Kerman RH, Van Buren CT, Wideman C, Kahan BD. Does cyclosporine influence the results of cadaver retransplantation? Hum Immunol 1985, 14:305.
8. Ahmed K, Ahmad N, Khan MS. Influence of number of retransplants on renal graft outcome. Transplant Proc 2008, 40:1349.
9. Sehgal SN. Rapamune (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998, 31:335.
10. MacDonald AS. A world-wide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation 2001, 71:271.
11. Kahan BD. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: a randomised multicentre study. Lancet 2000, 356.
12. Moon JI, Kim YS, Kim MS. Effect of cyclosporine, mycophenolic acid, and rapamycin on the proliferation of rat aortic vascular smooth muscle cells: in vitro study. Transplant Proc 2000, 32:2026.
13. Wang W, Chan YH, Lee W, Chan L. Effect of rapamycin and FK 506 on mesangial cell proliferation. Transplant Proc 2001, 33:1036.
14. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with Target-of-Rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005, 80:883.
15. Podder H, Kahan BD. Individualization of immunosuppressive therapy I: Sirolimus improves outcomes in African-American renal transplant recipients. Transplant Proc 2005, 37:3723.
16. Kerman RH, Kimball PM, Van Buren CT. Possible contribution of pretransplant immune responder status to renal allograft survival differences of black versus white recipients. Transplantation 1991, 51:338.
17. Kahan BD, Podbielski J, Napoli KL, Katz SM, Meier-Kriesche H-U, Van Buren CT. Immunosuppressive effects and safety of a sirolimus/cyclosporine combination regimen for renal transplantation. Transplantation 1998, 66:1040.
18. Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J. Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: a phase II trial. Transplantation 1999, 68:1526.
19. Benavides CA, Pollard VB, Mauiyyedi S, Podder H, Knight R, Kahan BD. BK virus associated nephropathy in sirolimus treated renal transplant patients: incidence, course, and clinical outcomes. Transplantation 2007, 84:83.
20. Kaposztas Z, Podder H, Mauiyyedi S. Impact of rituximab therapy for treatment of acute humoral rejection. Clin Transplant 2009, 23:63.
21. Pour-Reza-Gholi F, Nafar M, Saeedinia A. Kidney retransplantation in comparison with first kidney transplantation. Transplant Proc 2005, 37:2962.
22. Etienne T, Goumaz C, Ruedin P, Jeannet M. Renal retransplantation in Switzerland; poor HLA matching of first and subsequent allografts does not appear to affect overall graft survival. Transpl Int 1992, 5:S65.
23. Delmonico FL, Tolkoff-Rubin N, Auchincloss H. Second renal Transplantations. Ethical issues clarified by outcome; outcome enhanced by a reliable crossmatch. Arch Surg 1994, 129:354.
24. Stratta RJ, Oh CS, Sollinger HW, Pirsch JD, Kalayoglu M, Belzer FO. Kidney retransplantation in the cyclosporine era. Transplantation 1988, 45:40.
25. Yagmurdur MC, Emiroĝlu R, Ayvaz I, Sozen H, Karakayali H, Haberal M. The effect of graft nephrectomy on long-term graft function and survival in kidney retransplantation. Transplant Proc 2005, 37:2957.
26. Gjertson DW. A multi-factor analysis of kidney regraft outcomes. Clin Transplant 2002
27. Ott U, Busch M, Steiner T, Schubert J. Renal retransplantation - a retrospective monocentric study. Transplant Proc 2008, 40:1345.
28. Goldfarb-Rumyantzev AS, Hurdle JF, Baird BC. The role of pre-emptive transplant graft and recipient outcome. Nephrol Dial Transplant 2006, 21:1355.
29. El-Agroudy AE, Wafa EW, Bakr MA. Living-donor kidney retransplantation: risk factors and outcome. BJU Int 2004, 94:369.
30. Hardy S, Lee SH, Terasaki PI, Cecka JM, Terasaki PI. Sensitization 2001. 2001, 271. In, eds, Clinical Transplants. Los Angeles: UCLA Immunogenetics Center